Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
NL-OMON32569Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of panobinostat in breast cancer (2 arms), sponsored by Novartis. Primary endpoints: Maximum tolerated dose of intravenous panobinostat and Maximum tolerated dose of oral panobinostat. Planned start Dec 2008; status: not yet recruiting.
02
Drugs
panobinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON32569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32569.